Patrys to initiate an Investigator-Sponsored
Clinical Trial using PAT-SM6 in combination
with Onyx Pharmaceuticals’ carfilzomib
Combination study with Patrys’ PAT-SM6 and Onyx Pharmaceuticals’ carfilzomib
Trial to be conducted at the University of Würzburg, Germany under the leadership of
Professor Dr. Hermann Einsele, a world-acclaimed expert in blood cancers
Melbourne, Australia; 11 November, 2013: Patrys Limited (ASX: PAB), a clinical stage biotechnology
company has today announced that it is initiating an investigator-sponsored trial (IST) evaluating the
effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients
with relapsed and refractory multiple myeloma (MM). The trial will be headed by Professor Dr.
Hermann Einsele, Director of the Department of Medicine II, University of Würzburg, Germany, and
is being funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
Both clinical and preclinical studies of PAT-SM6 conducted to date have shown evidence of activity in
patients with relapsed and refractory MM. One of the notable features of PAT-SM6, being
demonstrated in the currently-ongoing Phase I/IIa clinical trial, is the lack of serious side-effects in
treated patients. This feature of PAT-SM6 may allow it to be safely administered in combination with
carfilzomib and may have the potential to improve current treatments for MM. Carfilzomib is a
proteasome inhibitor owned by Onyx, and is marketed in the United States (U.S.) under the brand
name Kyprolis® (carfilzomib) for Injection. Onyx will provide carfilzomib study drug for the trial.